A 5-lipoxygenase inhibitor, FR110302, suppresses airway hyperresponsiveness and lung eosinophilia induced by Sephadex particles in rats.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Agents and Actions

• Publication date

  1992-07-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  PMID 1382375
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.

  1991cited by this paper
• Production of leukotrienes in phorbol ester-induced acute lung injury.

  1990cited by this paper
• Eosinophil supernatant causes hyperresponsiveness of airway smooth muscle in guinea pig trachea.

  1990cited by this paper
• The effects of drugs on Sephadex‐induced eosinophilia and lung hyper‐responsiveness in the rat

  1990cited by this paper
• Correlation between blood eosinophilia and airways hyper-responsiveness in rats.

  1989cited by this paper
• The effect of leukotriene antagonists, lipoxygenase inhibitors and selected standards on leukotriene-mediated allergic bronchospasm in guinea pigs

  1989cited by this paper
• New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma.

  1989cited by this paper
• Comparative studies of human eosinophil migration towards platelet-activating factor and leukotriene B4.

  1989cited by this paper
• Platelet-activating factor as a mediator of allergic disease.

  1988cited by this paper
• Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine.

  1987cited by this paper
• Peripheral blood eosinophil counts and bronchial responsiveness.

  1987cited by this paper
• Effects of leukotriene B4 inhalation. Airway sensitization and lung granulocyte infiltration in the guinea pig.

  1987cited by this paper
• Airway hyper-reactivity and blood, lung and airway eosinophilia in rats treated with Sephadex particles.

  1986cited by this paper
• Characterization of the airway response to inhaled leukotriene D4 in normal subjects.

  1986cited by this paper
• The eosinophil and the pathophysiology of asthma.

  1986cited by this paper
• Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man.

  1986cited by this paper
• Airway hyperresponsiveness induced by platelet-activating factor: role of thromboxane generation.

  1986cited by this paper
• Ozone-induced bronchial hyperreactivity in guinea pigs is abolished by BW 755C or FPL 55712 but not by indomethacin.

  1985cited by this paper
• Increased biosynthesis of platelet-activating factor in activated human eosinophils.

  1984cited by this paper
• Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4.

  1983cited by this paper
• Leukotriene generation by eosinophils

  1982cited by this paper

• Uridine, 4-thiouridine and isomaltitol in an asthma-like model Anti-inflammatory and modulating effects

  2009cites this paper
• YM-341619 suppresses the differentiation of spleen T cells into Th2 cells in vitro, eosinophilia, and airway hyperresponsiveness in rat allergic models.

  2008cites this paper
• A 5-lipoxygenase inhibitor, FR110302, inhibits ozone-induced airway hyperresponsiveness in guinea pigs and dogs

  2005cites this paper
• A new class of nonpeptide bradykinin B(2) receptor ligand, incorporating a 4-aminoquinoline framework. Identification of a key pharmacophore to determine species difference and agonist/antagonist profile.

  2004cites this paper
• A new series of highly potent non-peptide bradykinin B2 receptor antagonists incorporating the 4-heteroarylquinoline framework. Improvement of aqueous solubility and new insights into species difference.

  2004cites this paper
• Pharmacology of the eosinophil.

  1999cites this paper
• Novel Inhibitors of Leukotrienes

  1999cites this paper
• SmithKline Beecham Pharmaceuticals’ cysteinyl leukotriene receptor antagonists: Pranlukast (SB 205312; Ono-1078; Onon), Pobilukast (SK&F 104353) and SK&F 106203

  1999cites this paper
• PULMONARY INFLAMMATION WITHOUT BRONCHIAL HYPERRESPONSIVENESS IN VIVO OR IN VITRO AFTER SEPHADEX INSTILLATION IN PIGS

  1999cites this paper
• A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety.

  1998cites this paper
• A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man.

  1998cites this paper
• Inhibition of Pulmonary Eosinophilia Does Not Necessarily Prevent the Airway Hyperresponsiveness Induced by Sephadex Beads

  1998cites this paper
• A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework.

  1998cites this paper
• Studies on 5-lipoxygenase inhibitors. II. Discovery, optical resolution and enantioselective synthesis of FR110302, a highly potent non-redox type 5-lipoxygenase inhibitor.

  1998cites this paper
• A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation.

  1998cites this paper
• Pharmacological characterization of a novel, orally active, nonpeptide bradykinin B2 receptor antagonist, FR167344.

  1997cites this paper
• Characterization of FR173657, a novel nonpeptide B2 antagonist: in vitro and in vivo studies.

  1997cites this paper
• Tumour necrosis factor‐α expression and cell recruitment in Sephadex particle‐induced lung inflammation: effects of dexamethasone and cyclosporin A

  1997cites this paper
• The identification of an orally active, nonpeptide bradykinin B2 receptor antagonist, FR173657

  1997cites this paper
• Inhibition of Sephadex-induced lung injury in the rat by Ro 45-2081, a tumor necrosis factor receptor fusion protein.

  1996cites this paper
• Possible role of thromboxane A2 in hyperresponsiveness of isolated rat lung tissue in a Sephadex-induced eosinophilia model.

  1995cites this paper
• Leukotriene and thromboxane antagonists

  1994cites this paper